We as humans have come very far in terms of scientific discoveries and technological inventions. we are living longer than ever before and understanding a lot more than our ancestors about the world around us. with that being said, their are a few things in the world currently that we are still shook on and cant seem to figure out how to manage quickly and easily. One of those things is the scourge wreaking havoc across the globe known as cancer. When you have a sickness like this that seems to permeate from generation to generation there is only one thing to do. Call on someone who specializes in these matters and that’s who Clay Siegall is.
Clay Siegall is the founder and CEO of Seattle Genetics, a company dedicated to taking down especially strong or not much improved on diseases and sicknesses. Armed with a PhD from George Washington state and B.S. in zoology, Clay Siegall and his company have developed substantial therapy drugs helping to stop cancer and other diseases that have had little improvement. Since starting his company in 1998 due to wanting to be his own boss, Clay has taken his company to the top of the industry with accolades like developing the first FDA-approved antibody drug conjugate. Like many others according to Siegall he had to watch the way cancer and the not so gentle remedies for it ravage a family members body. The member almost dying from the treatment and not the disease itself is one of the main reasons he decided to choose this line of work with him thinking”there has to be a better way.” Though it hasn’t always been easy to run the business with things according to Clay getting “a little hairy” around 1999 and 2000. Clay uses his belief in hard work, which he believes is the main contributor to his success to find the way out and the next big breakthrough in medicine.
Clay Siegall has 15 patents and over 20 different drugs on the market to vouch for the success he has obtained. Furthermore, his company has over 675 million from public and private financers. His resume as being Board of Directors of Alder Biopharmaceuticals, a part of the National Cancer Institute from 1988 to 1991, and the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 shows his dedication and knowledge of his craft. Clay Siegall is the author of over 70 publications so its safe to say he is capable of writing cancer off. They always said you need the right man for the right job and that very well maybe who Clay Siegall is.